Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 1200020160400040283
Diabetes & Metabolism Journal
2016 Volume.40 No. 4 p.283 ~ p.289
Glycemic Effects of Rebaudioside A and Erythritol in People with Glucose Intolerance
Shin Dong-Hee

Lee Ji-Hye
Kang Myung-Shin
Kim Tae-Hoon
Jeong Su-Jin
Kim Chong-Hwa
Kim Sang-Soo
Kim In-Joo
Abstract
Background: Rebaudioside A and erythritol are nonnutritive sweeteners. There have been several studies of their glycemic effects, but the outcomes remain controversial. The purpose of this study was to evaluate the glycemic effects of rebaudioside A and erythritol as a sweetener in people with glucose intolerance.

Methods: This trial evaluated the glycemic effect after 2 weeks of consumption of rebaudioside A and erythritol as sweeteners in a pre-diabetic population. The patients were evaluated for fructosamine, fasting plasma glucose, C-peptide, insulin, and 2-hour plasma glucose before and after consumption of sweetener. The primary outcome was a change in fructosamine levels from the baseline to the end of treatment. Secondary outcomes were the changes in levels of fasting plasma glucose and 2-hour plasma glucose.

Results: From the baseline to the end of experiment, the changes in fructosamine levels after consumption of rebaudioside A and erythritol, did not differ significantly (244.00¡¾19.57 vs. 241.68¡¾23.39 ¥ìmol/L, P=0.366). The change in levels from the baseline to end of the study for rebaudioside A and erythritol were fasting plasma glucose (102.56¡¾10.72 vs. 101.32¡¾9.20 mg/dL), 2-hour plasma glucose (154.92¡¾54.53 vs. 141.92¡¾42.22 mg/dL), insulin (7.56¡¾4.29 vs. 7.20¡¾5.12 IU/mL), and C-peptide (2.92¡¾1.61 vs. 2.73¡¾1.31 ng/mL), respectively, and also did not differ significantly (P>0.05 for all).

Conclusion: Our study suggests that consumption of rebaudioside A and erythritol does not alter the glucose homeostasis in people with glucose intolerance.
KEYWORD
Erythritol, Glucose intolerance, Rebaudioside A
FullTexts / Linksout information
Listed journal information
SCI(E) ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø